CDK4/6 inhibitors plus endocrine therapy vs. placebo plus endocrine therapy for HR+/HER2-advanced breast cancer: a phase III RCTs based meta-analysis
Favorite
Share
More Options
Fullscreen
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
